https://www.live-feeds.com/feed/novo-nordisk-says-wegovy-shot-helped-children-lose-weight-in-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-says-wegovy-shot-helped-children-lose-weight-in-trialhttps://www.live-feeds.com/feed/novo-nordisk-says-wegovy-shot-helped-children-lose-weight-in-trial#u61951Tue, 08 Sep 2026 22:43:41 +0000Novo Nordisk announced that its Phase 3 STEP Young trial met its primary endpoint, demonstrating that once-weekly semaglutide injections reduced obesity rates and lowered BMI in children aged 6 to under 12. Data shows 40.4% of children in the trial saw a positive response. The results target a demographic with limited existing weight loss therapeutic options. Despite the clinical success, Novo Nordisk shares fell nearly 2% following the announcement, which coincided with the cancellation of two other trials.Why it mattersWegovy is an injectable weight-loss drug based on semaglutide. Expanding